Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 11/2023

02-09-2023 | Eosinophilic Esophagitis

Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies

Authors: Colby S. Sharlin, Vincent A. Mukkada, Philip E. Putnam, Scott M. Bolton

Published in: Current Gastroenterology Reports | Issue 11/2023

Login to get access

Abstract

Purpose of Review

This review presents and summarizes the existing studies on the treatment goals and options for pediatric eosinophilic esophagitis utilizing rigorous peer-reviewed literature.

Recent Findings

In addition to traditional treatments, emerging biologic therapies continue to evolve the approach to treating pediatric eosinophilic esophagitis. Well defined treatment goals will aid the continued development of new therapies. Further, innovative assessment tools have changed how the clinician is able to assess the effectiveness of therapies with a trend toward less invasive options.

Summary

The management of pediatric eosinophilic esophagitis continues to evolve with the advent of both novel treatment options and assessment tools. Treatment choices, with benefits and risks involved, should be presented to families upon diagnosis and tailored towards the individual patient and likelihood of adherence and success. Biologic therapy for EoE presents an exciting option for both first line therapy and escalation for those with severe or unresponsive disease.
Literature
1.
Dellon ES, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022–1033e10. The most recent consensus guidelines regarding the diagnosis of eosinohpilic esophagitis. These guidelines removed the prior diagnostic requirement that patients must first fail a trial of proton pump inhibitor.PubMedCrossRef
2.
Arias A, et al. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016;43(1):3–15.PubMedCrossRef
3.
Allin KH, et al. Eosinophilic oesophagitis in Denmark: Population-based incidence and prevalence in a nationwide study from 2008 to 2018. United Eur Gastroenterol J. 2022;10(7):640–50.CrossRef
4.
Dellon ES, Hirano I. Epidemiology and natural history of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):319–332e3.PubMedCrossRef
5.
Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9.PubMedCrossRef
6.
Warners MJ, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol. 2018;113(6):836–44.PubMedCrossRef
7.
Pentiuk S, et al. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;48(2):152–60.PubMedPubMedCentralCrossRef
8.
Safroneeva E, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150(3):581–590e4.PubMedCrossRef
9.
Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840–51.PubMedCrossRef
10.
Ma C, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022;149(2):659–70. Established the first core outcome set for both adult and pediatric eosinophilic esophagitis treatment. This will enable a more uniform approach to research and clinical trials.PubMedCrossRef
11.
12.
Collins MH, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8. Developed and validated the first histologic scoring system for eosinophilic esophagitis which evaluates histopathologic findings beyond peak eosinophil count. This may prove to be even more relevant in light of a shifting understanding of disease pathology that eosinophils may not drive inflammation and fibrosis.PubMed
13.
Ma C, et al. Responsiveness of a histologic Scoring System compared with peak Eosinophil Count in Eosinophilic Esophagitis. Am J Gastroenterol. 2022;117(2):264–71.PubMedCrossRef
14.
Kliewer KL, et al. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol; 2023.
15.
Wechsler JB, et al. Eosinophilic esophagitis reference score accurately identifies Disease Activity and Treatment Effects in Children. Clin Gastroenterol Hepatol. 2018;16(7):1056–63.PubMedCrossRef
16.
Ahuja N, et al. Applying the eosinophilic Esophagitis Endoscopic reference scores (EREFS) to different aged children. J Pediatr Gastroenterol Nutr. 2020;71(3):328–32.PubMedCrossRef
17.
Dellon ES, et al. Accuracy of the eosinophilic Esophagitis Endoscopic reference score in diagnosis and determining response to treatment. Clin Gastroenterol Hepatol. 2016;14(1):31–9.PubMedCrossRef
18.
Hudgens S, et al. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017;1(1):3.PubMedPubMedCentralCrossRef
19.
Franciosi JP, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11:126.PubMedPubMedCentralCrossRef
20.
Aceves SS, et al. Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol. 2018;142(1):130–138e1.PubMedPubMedCentralCrossRef
21.
Warners MJ, et al. Systematic review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017;112(11):1658–69.PubMedCrossRef
22.
Lynch MK, et al. Disease-Related predictors of Health-Related Quality of Life in Youth with Eosinophilic Esophagitis. J Pediatr Psychol. 2018;43(4):464–71.PubMedCrossRef
23.
Dellon ES, et al. A clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and future directions. Gastroenterology. 2022;163(1):59–76.PubMedCrossRef
24.
Kelly KJ et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula Gastroenterology, 1995. 109(5): p. 1503-12. ● A key study which first demonstrated food allergen elimination led to improvement in eosinophilic esophagitis histology.
25.
Arias A, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–48.PubMedCrossRef
26.
Philpott H, et al. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016;44(3):223–33.PubMedCrossRef
27.
Rank MA, et al. Technical Review on the management of eosinophilic esophagitis: a Report from the AGA Institute and the Joint Task Force on Allergy-Immunology practice parameters. Gastroenterology. 2020;158(6):1789–1810e15.PubMedCrossRef
28.
Eckmann JD, et al. Efficacy of Atopy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: a pilot study. Dig Dis Sci. 2018;63(3):694–702.PubMedCrossRef
29.
Kagalwalla AF, et al. Efficacy of a 4-Food elimination Diet for Children with Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2017;15(11):1698–1707e7.PubMedPubMedCentralCrossRef
30.
Molina-Infante J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–72. Changed the practice of diet therapy to a step-up approach which offers patients a more limited number of eliminations at initiation and only expanding eliminations if necessary to achieve remission. This approach was demonstrated to require fewer dietary restrictions and endoscopies, shortening the time needed to identify food allergent triggers.PubMedCrossRef
31.
Gonsalves N, Schwartz DB, Yang S, Zalewski GY, Amsden A, Mughal K, Manuel-Rubio S, Melin-Aldana M, Wershil H, Hirano BK, Kagalwalla I. Prospective trial of four food elimination diet demonstrates comparable effectiveness in the treatment of adult and pediatric eosinophilic esophagitis. Gastroenterology. 2013;144:S154.CrossRef
32.
Mayerhofer C, et al. Efficacy of Elimination Diets in Eosinophilic Esophagitis: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol; 2023.
33.
Kruszewski PG, et al. Prospective, comparative effectiveness trial of cow’s milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus. 2016;29(4):377–84.PubMedCrossRef
34.
Wechsler JB, Ross SS, Makhija J, Shaykin MM, Amsden R, Johnson K, Sulkowski K, Wershil M, Melin-Aldana BK, Kagalwalla H. Cow’s milk elimination for treatment of eosinophilic esophagitis: a prospective Pediatric Study. Gastroenterology. 2017;152(5):S855.CrossRef
35.
Kliewer K, Atkins AS, Bonis D, Chehade PA, Collins M, Dellon MH, Fei ES, Gupta L, Kagalwalla SK, Mir AF, Mukkada S, Pesek V, Spergel R, Yang J, Rothenberg G. 817 – efficacy of 1-Food and 4-Food elimination diets for Pediatric Eosinophilic Esophagitis in a randomized multi-site study. Gastroenterology. 2019;156(6):S–172.CrossRef
36.
Philpott H, Dellon E. Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy. 2018;8(2):e20.PubMedPubMedCentralCrossRef
37.
Chang JW, et al. Development of a practical guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol; 2023.
38.
Groetch M, et al. Dietary therapy and Nutrition Management of Eosinophilic Esophagitis: a Work Group Report of the American Academy of Allergy, Asthma, and Immunology. J Allergy Clin Immunol Pract. 2017;5(2):312–324e29.PubMedCrossRef
39.
Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):66–76. e3.PubMedCrossRef
40.
Murali AR, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111–9.PubMedCrossRef
41.
Rawla P, et al. Efficacy and safety of Budesonide in the treatment of eosinophilic esophagitis: updated systematic review and Meta-analysis of Randomized and Non-Randomized Studies. Drugs R D. 2018;18(4):259–69.PubMedPubMedCentralCrossRef
42.
Dellon ES, et al. Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(4):666–673e8.PubMedCrossRef
43.
Dellon ES, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152(4):776–786e5.PubMedCrossRef
44.
Hirano I, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20(3):525–534e10.PubMedCrossRef
45.
Lucendo AJ, et al. Efficacy of Budesonide Orodispersible Tablets as induction therapy for eosinophilic esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology. 2019;157(1):74–86e15.PubMedCrossRef
46.
Butz BK et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology, 2014. 147(2): p. 324 – 33 e5.
47.
Ketchem CJ et al. Treatment with compounded fluticasone suspension improves the clinicndoscopic, and histologic features of eosinophilic esophagitis. Dis Esophagus, 2021. 34(7).
48.
Andreae DA, et al. Swallowed Fluticasone Propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis. Am J Gastroenterol. 2016;111(8):1187–97.PubMedPubMedCentralCrossRef
49.
Dellon ES, et al. Efficacy of Budesonide vs Fluticasone for initial treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. Gastroenterology. 2019;157(1):65–73. e5.PubMedCrossRef
50.
Nistel M, et al. Ciclesonide Impacts Clinicopathological features of Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2021;9(11):4069–74.PubMedCrossRef
51.
Jensen ET, et al. Longitudinal growth outcomes following first-line treatment for Pediatric patients with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;68(1):50–5.PubMedPubMedCentralCrossRef
52.
Golekoh MC, et al. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr. 2016;170:240–5.PubMedCrossRef
53.
Hsu S, et al. Adrenal insufficiency in Pediatric Eosinophilic Esophagitis Patients treated with swallowed topical steroids. Pediatr Allergy Immunol Pulmonol. 2017;30(3):135–40.PubMedPubMedCentralCrossRef
54.
Bose P, et al. Adrenal insufficiency in children with eosinophilic esophagitis treated with topical corticosteroids. J Pediatr Gastroenterol Nutr. 2020;70(3):324–9.PubMedCrossRef
55.
Ahmet A, et al. Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2016;12:49.PubMedPubMedCentralCrossRef
56.
Philpott H, et al. Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(8):1071–8.PubMedPubMedCentralCrossRef
57.
Franciosi JP, et al. Proton Pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy. 2022;15:281–302.PubMedPubMedCentralCrossRef
58.
Liacouras CA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20. e6; quiz 21 – 2.PubMedCrossRef
59.
Dellon ES et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol, 2013. 108(5): p. 679 – 92; quiz 693.
60.
Molina-Infante J, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65(3):524–31.PubMedCrossRef
61.
Navarro P, et al. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis. 2021;53(11):1479–85.PubMedCrossRef
62.
Thakkar KP, et al. Effect of Proton pump inhibitor treatment in PPI non-responsive patients with eosinophilic esophagitis. J Gastrointestin Liver Dis. 2023;32(1):15–22.PubMedCrossRef
63.
Lucendo AJ, Arias A, Molina-Infante J. Efficacy of Proton Pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22e1.PubMedCrossRef
64.
Thakkar KP, et al. Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis. Dig Liver Dis. 2022;54(9):1179–85.PubMedPubMedCentralCrossRef
65.
Gutierrez-Junquera C, et al. Proton Pump inhibitor therapy in Pediatric Eosinophilic Esophagitis: predictive factors and long-term step-down efficacy. J Pediatr Gastroenterol Nutr. 2023;76(2):191–8.PubMedCrossRef
66.
67.
Hirano I, et al. Efficacy of Dupilumab in a phase 2 Randomized Trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122e10.PubMedCrossRef
68.
Dellon ES, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317–30. Results of the pivotal trials of dupilumab which is the first, and only, FDA approved medication to treat adolescent and adult eosinophilic esophagitis. It also represents the first time a biologic has been employed to treat eosinophilic esophagitis, laying the foundation for future biologic trials.PubMedCrossRef
69.
Dellon ES, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19(3):473–483e17.PubMedCrossRef
70.
Chretien B, et al. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase((R)). Br J Dermatol. 2021;185(2):464–5.PubMedCrossRef
71.
Bachert C, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–50.PubMedCrossRef
72.
Spergel BL, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589–93.PubMedCrossRef
73.
Aceves SS, et al. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: a yardstick. Ann Allergy Asthma Immunol. 2023;130(3):371–8.PubMedCrossRef
74.
Schoepfer AM, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol. 2010;105(5):1062–70.PubMedCrossRef
75.
Moawad FJ, et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96–105.PubMedCrossRef
76.
Moole H, et al. Role of endoscopic esophageal dilation in managing eosinophilic esophagitis: a systematic review and meta-analysis. Med (Baltim). 2017;96(14):e5877.CrossRef
77.
Reed CC, et al. Combined and alternating topical steroids and Food Elimination Diet for the treatment of Eosinophilic Esophagitis. Dig Dis Sci. 2018;63(9):2381–8.PubMedPubMedCentralCrossRef
78.
Reed CC, et al. Combination Therapy with Elimination Diet and Corticosteroids is effective for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(13):2800–2.PubMedPubMedCentralCrossRef
79.
Heine RG, Cameron PR, Alex DJ, Oliver G, Hardikar MR, Chow W, McWilliam CW, Moore VL, Kakakios DJ, Cheah AM, O’Loughlin E, Axelrad E, Allen C. Effect of a 4-food elimination diet and omeprazole in children with eosinophilic esophagitis – a randomized, controlled trial. J Allergy Clin Immunol. 2019;143(2):AB309.CrossRef
80.
Koutlas NT, Dellon ES. Progression from an inflammatory to a fibrostenotic phenotype in Eosinophilic Esophagitis. Case Rep Gastroenterol. 2017;11(2):382–8.PubMedPubMedCentralCrossRef
81.
Dellon ES, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577–85e4. ● This retrospective, cross-sectional study of children and adults who have eosinophilic esophagitis found that the risk of developing a fibrostenotic disease phenotype doubled with every 10 years of life. These findings contribute to the recognition of eosinophilic esophagitis as progressive disease that necessitates treatment depsite the presence of current symptoms.PubMedCrossRef
82.
Schoepfer AM, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–6e1.PubMedCrossRef
83.
Lipka S, Kumar A, Richter JE. Impact of Diagnostic Delay and other Risk factors on eosinophilic Esophagitis phenotype and esophageal diameter. J Clin Gastroenterol. 2016;50(2):134–40.PubMedCrossRef
84.
Dellon ES, et al. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol. 2015;28(3):383–90.PubMedCrossRef
85.
Shah A, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol. 2009;104(3):716–21.PubMed
86.
Arnim UV, et al. Monitoring patients with eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. Clin Gastroenterol Hepatol; 2022.
87.
Godwin B, Wilkins B, Muir AB. EoE disease monitoring: where we are and where we are going. Ann Allergy Asthma Immunol. 2020;124(3):240–7.PubMedCrossRef
88.
Hoffmann NV, Keeley K, Wechsler JB. Esophageal distensibility defines fibrostenotic severity in Pediatric Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2023;21(5):1188–97. e4.PubMedCrossRef
Metadata
Title
Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies
Authors
Colby S. Sharlin
Vincent A. Mukkada
Philip E. Putnam
Scott M. Bolton
Publication date
02-09-2023
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 11/2023
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-023-00893-6

Other articles of this Issue 11/2023

Current Gastroenterology Reports 11/2023 Go to the issue

ReviewPaper

Update on Cystic Fibrosis in Pediatric Patients

ReviewPaper

Climate Change and the Esophagus: Speculations on Changing Disease Patterns as the World Warms

ReviewPaper

Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease

ReviewPaper

Treatment of Cholestasis in Infants and Young Children

ReviewPaper

Point-of-Care Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease

ReviewPaper

Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits